Analysts Set Expectations for SLXN FY2027 Earnings

Silexion Therapeutics Corp (NASDAQ:SLXN) – Investment analysts at Litchfield Hills Research issued their FY2027 EPS estimates for shares of Silexion Therapeutics in a research report issued to clients and investors on Monday, September 21st. Litchfield Hills Research analyst T. O’neill anticipates that the company will post earnings per share of ($1.84) for the year. The consensus estimate for Silexion Therapeutics’ current full-year earnings is ($45.50) per share.

Silexion Therapeutics (NASDAQ:SLXN) last issued its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($21.20) by $16.03.

A number of other research analysts have also recently issued reports on SLXN. Maxim Group cut Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Friday, September 11th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Silexion Therapeutics presently has a consensus rating of “Hold”.

Silexion Therapeutics Price Performance

Shares of SLXN opened at $0.54 on Tuesday. Silexion Therapeutics has a one year low of $0.32 and a one year high of $42.60. The firm has a market capitalization of $3.03 million, a PE ratio of -0.01 and a beta of -0.36. The company has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $5.48.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing RNA-based treatments for solid tumors driven by mutations in the KRAS gene. The company’s research is centered on gene-silencing technologies designed to inhibit KRAS, an important cancer-promoting protein that has historically been difficult to target with conventional therapies.

Silexion’s development programs include SIL-204, an investigational small interfering RNA (siRNA) therapy designed to target KRAS mutations, including KRAS G12D, a frequently observed mutation in pancreatic cancer.